Pictilisib plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

The PEGGY study failed to meet its primary endpoint, with no improvement in progression-free survival in patients who received pictilisib plus paclitaxel versus placebo plus paclitaxel in either the intention-to-treat population or in patients with PIK3CA-mutated tumours.

from Cancer via ola Kala on Inoreader http://ift.tt/2bMla2b
via IFTTT